VERONA PHARMA SP.ADR 8

Historical 13F Holders

Symbol
VRNA
CUSIP
925050106
All holders as of
Q4 2025
Type
Equity
Class
SPONSORED ADS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 925050106 since 12/18/2024, newest first.

Filer % of Class Filed
Janus Henderson Group PLC 13G/A Amendment 2 1.2% 11/14/2025
Event 9/30/2025
Perceptive Advisors LLC 13G/A Amendment 3
0% 11/14/2025
Event 9/30/2025
Pentwater Capital Management LP 13G
0% 11/14/2025
Event 9/30/2025
RA Capital Management, L.P. 13G/A Amendment 7
0.7% 8/14/2025
Event 6/30/2025
Janus Henderson Group PLC 13G/A Amendment 1 7.2% 8/14/2025
Event 6/30/2025
Perceptive Advisors LLC 13G/A Amendment 2
6.4% 8/14/2025
Event 6/30/2025
RA Capital Management, L.P. 13G/A Amendment 6
7.1% 5/15/2025
Event 3/31/2025
Janus Henderson Group PLC 13G 6.5% 5/14/2025
Event 3/31/2025
RA Capital Management, L.P. 13G/A Amendment 5
8.9% 2/14/2025
Event 12/31/2024
Maverick Capital, Ltd. 13G/A Amendment 1
3.8% 2/14/2025
Event 12/31/2024
Growth Equity Opportunities Fund IV, LLC 13D/A Amendment 4
4.99% 1/21/2025
Event 1/16/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q4 1 20.0 k $359 k
2025 Q3 268 82.0 M $8.75 B
2025 Q2 319 77.5 M $7.33 B
2025 Q1 286 72.3 M $4.58 B
2024 Q4 216 68.6 M $3.19 B
2024 Q3 165 67.7 M $1.95 B
2024 Q2 138 67.1 M $970 M
2024 Q1 122 67.6 M $1.10 B
2023 Q4 131 68.4 M $1.36 B
2023 Q3 111 65.3 M $1.07 B
2023 Q2 112 62.9 M $1.33 B
2023 Q1 103 60.4 M $1.22 B
2022 Q4 105 54.4 M $1.31 B
2022 Q3 77 52.4 M $532 M
2022 Q2 43 35.1 M $146 M
2022 Q1 41 36.4 M $182 M
2021 Q4 48 39.8 M $267 M
2021 Q3 41 37.0 M $203 M
2021 Q2 39 39.6 M $259 M
2021 Q1 40 39.4 M $329 M
2020 Q4 40 35.7 M $246 M
2020 Q3 30 34.1 M $213 M
2020 Q2 19 7.17 M $33.6 M
2020 Q1 15 6.98 M $28.8 M
2019 Q4 15 5.85 M $33.7 M
2019 Q3 14 5.86 M $26.8 M
2019 Q2 18 7.37 M $37.6 M
2019 Q1 19 7.38 M $47.5 M
2018 Q4 19 8.41 M $78.6 M
2018 Q3 17 7.38 M $92.4 M
2018 Q2 15 6.50 M $71.2 M
2018 Q1 15 6.58 M $132 M
2017 Q4 12 6.68 M $79.3 M
2017 Q3 10 5.28 M $81.0 M
2017 Q2 9 3.95 M $46.1 M